FDA-Approved Ovarian Cancer Drug Treatments
| FDA-APPROVED OVARIAN CANCER TREATMENTS | ||||
|---|---|---|---|---|
| Generic & Class | Brand & Company | Strength | Form | Usual Dose* |
| Alkylating agent | ||||
| Altretamine | Hexalen
(MGI Pharma) |
50mg | caps | 260mg/m² daily in four divided doses for either 14 or 21 consecutive days in a 28 day cycle |
| Carboplatin | (various) | 10mg/mL | soln for IV infusion | Advanced ovarian cancer (previously untreated): 300mg/m² on Day 1
every 4 weeks for 6 cycles
Recurrent ovarian cancer: 360mg/m² on Day 1 every 4 weeks |
| Cisplatin | (various) | 1mg/mL | soln for IV infusion after dilution | 100mg/m² once every 4 weeks |
| Cyclophosphamide | (various) | 25mg, 50mg | tabs | 1–5mg/kg/day |
| Cytoxan injection
(Bristol Myers Squibb) |
500mg, 1g, 2g | pwd for inj after reconstitution | 40–50mg/kg in divided doses over 2–5 days or 10–15mg/kg every 7–10 days or 3–5mg/kg twice weekly | |
| Melphalan | Alkeran
(GlaxoSmithKline) |
2mg | scored tabs | 0.2mg/kg/day for 5 days; repeat every 4–5 weeks |
| Thiotepa | (various) | 15mg | pwd for IV, intravesical, or intracavitary administration after reconstitution | 0.3–0.4mg/kg IV once every 1–4 weeks |
| Antibiotics (cytotoxic) | ||||
| Doxorubicin | Adriamycin
(Bedford) |
10mg, 20mg, 50mg | pwd for IV inj after reconstitution | Monotherapy: 60–75mg/m² every 21 days
Combination therapy: 40–60mg/m² every 21 to 28 days |
| Adriamycin Solution
(Bedford) |
2mg/mL | soln for IV inj | ||
| Doxorubicin (liposomal) | Doxil
(Janssen Biotech) |
2mg/mL | dispersion for IV infusion after dilution | 50mg/m² once every 4 weeks |
| Antimetabolite | ||||
| Gemcitabine | Gemzar
(Lilly) |
200mg, 1g | pwd for IV infusion after reconstitution | 1000mg/m² on Days 1 and 8 of each 21 day cycle |
| Hydroxyurea | Hydrea
(Bristol Myers Squibb) |
500mg | caps | Intermittant therapy: 80mg/kg as single dose every 3rd day
Continuous therapy: 20–30mg/kg/day as single dose |
| Antimicrotubule agents | ||||
| Paclitaxel | Taxol
(Bristol Myers Squibb) |
6mg/mL | soln for IV administration after dilution | Previously untreated ovarian cancer: 175mg/m² over 3 hours or
135mg/m2 over 24 hours; repeat every 3 weeks
Previously treated ovarian cancer: 135mg/m² or 175mg/m² over 3 hours every 3 weeks |
| Topoisomerase inhibitor | ||||
| Topotecan | Hycamtin
(GlaxoSmithKline) |
4mg | pwd for IV infusion after reconstitution and dilution | 1.5mg/m² daily for 5 consecutive days starting on Day 1 of a 21-day cycle |
| NOTES | ||||
|
* For more detailed dosing information, see drug entry. (Rev. 8/2012) |
||||
